NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases
Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases

NCT02288000

TerminatedPhase 1

Sponsor: University Hospital, Lille

Conditions: Alzheimer Disease, Battery

Interventions: Memantine, Placebo

Countries: France

The early assessment of new drugs for Alzheimer's disease remains difficult because of the lack of predictive end-point. The use of a battery including different parameters could improve this early development of new drugs. Nevertheless, the interest of such a battery should previously be validated with the yet marketed AD drugs.

Eligibility overview

Sex: MALE

Age: 18 Years to 30 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* 18-30 year old male non-smoker subjects
* Subject without cognitive impairment or cognitive complaint (Moca\>26, Mac Nair scale\<15)
* Subject without history of brain disease (severe brain trauma, stroke, cerebral tumor,…)
* Subject without major medical or surgical history
* Subject without current chronic disease
* Subject without current cerebral disease
* Subject without vascular or metabolic risk factor
* Subject without history or current mental disease or addiction (MINI)
* Subject without lesion on MRI
* Subject without abnormal electrical activities on EEG
* Subject without use of chronic treatment or psychotropic drugs or substances
* French speaker subject and able to understand the test instructions

Exclusion Criteria:

* Subject with dementia or cognitive decline identified by Moca \< 26
* Subject with vascular or metabolic risk factor
* Subject with history or current mental disease or addiction
* Subject with family history of young-onset dementia
* Subject with family history of chronic or severe neurological or mental disease (first degree relatives)
* Subject receiving a chronic treatment
* Subject with claustrophobia or contra-indication to MRI
* Subject unable to understand the test instructions
Locations (3)
  • Lille, France
  • Marseille, France
  • Toulouse, France